Framycetin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophthalmic Bacterial conjunctivitis; Blepharitis; Stye; Corneal abrasion As 0.5% solution/ointment: For rapid relief in acute conditions: Instill 1-2 drops to affected eye(s) 1-2 hourly for the 1st 2-3 days, then 1-2 drops 3-4 times/day when there is improvement. Otic Otitis externa As 0.5% solution: Instill 2-3 drops into the external auditory meatus tid. Max duration: 2 weeks. Topical Wounds, burns, ulcers and skin infections As dressing containing framycetin 1%: Apply a single layer directly to the wound. Change the dressing at least daily if wound is exudative. For leg ulcers, cut the dressing accurately to size of ulcer to avoid contact with surrounding healthy skin and to reduce the risk of sensitisation.
Dosage Details
Ophthalmic
Bacterial conjunctivitis, Blepharitis, Corneal abrasion, Stye
Adult: As 0.5% solution or ointment: For rapid relief in acute conditions: Instill 1-2 drops to affected eye(s) 1-2 hourly for the 1st 2-3 days. Reduce to 1-2 drops 3-4 times daily when there is improvement.
Child: Same as adult dose.

Otic/Aural
Otitis externa
Adult: As 0.5% solution: Instill 2-3 drops into the external auditory meatus tid. Max treatment duration: 2 weeks.
Child: Same as adult dose.

Topical/Cutaneous
Wounds, burns, ulcers and skin infections
Adult: As dressing containing framycetin 1%: Apply a single layer directly to the wound. Change the dressing at least daily if wound is exudative. For leg ulcers, cut the dressing accurately to size of ulcer to avoid contact with surrounding healthy skin and to reduce the risk of sensitisation.
Contraindications
Hypersensitivity to framycetin or other aminoglycoside antibacterials (neomycin, kanamycin). Perforated tympanic membrane (otic).
Special Precautions
Children. Pregnancy and lactation.
Adverse Reactions
Significant: Bacterial or fungal superinfection (prolonged use).
Ear and labyrinth disorders: Inner ear damage.
Eye disorders: Eye irritation, superficial punctate keratitis, delayed corneal epithelial wound healing, retinal toxicity (if there is leakage through corneoscleral wound).
Immune system disorders: Hypersensitivity reactions.
Patient Counseling Information
Ophthalmic: This drug may cause blurred vision, if affected, do not drive or operate machinery. If you are wearing contact lenses, remove prior to application and reinsert after 15 minutes.
MonitoringParameters
Monitor improvement of infection/symptoms.
Action
Description: Framycetin is an aminoglycoside bactericidal antibiotic. Its exact mechanism of action has not been fully elucidated; however, it appears to inhibit protein synthesis in susceptible bacteria by binding to ribosomal subunits. Framycetin is active against many aerobic gram-negative bacteria and some aerobic gram-positive bacteria.
Chemical Structure

Chemical Structure Image
Framycetin

Source: National Center for Biotechnology Information. PubChem Database. Neomycin, CID=8378, https://pubchem.ncbi.nlm.nih.gov/compound/Neomycin (accessed on Mar. 26, 2020)

Storage
Store between 15-25°C.
ATC Classification
D09AA01 - framycetin ; Belongs to the class of ointment dressings with antiinfectives.
S01AA07 - framycetin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
References
Anon. Framycetin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/11/2019.

Buckingham R (ed). Framycetin Sulfate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2019.

Joint Formulary Committee. Framycetin Sulfate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2019.

Sanofi-Aventis New Zealand Limited. Soframycin 5 mg/mL Ear/Eye Drops data sheet 25 January 2018. Medsafe. http://www.medsafe.govt.nz/. Accessed 11/11/2019.

Disclaimer: This information is independently developed by MIMS based on Framycetin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in